Phase
Condition
Macular Degeneration
Geographic Atrophy
Myopic Macular Degeneration
Treatment
Placebo
Tinlarebant
Clinical Study ID
Ages 12-20 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Subjects must have clinically diagnosed STGD1 with at least one mutation identifiedin the ABCA4 gene.
Subjects must have a defined aggregate atrophic lesion in 1 or both eyes.
Minimum BCVA is required in the study eye
Exclusion
Exclusion Criteria:
Any ocular disease other than STGD1 that, in the opinion of the investigator, wouldcomplicate assessment of a treatment effect.
History of ocular surgery in the study eye in the last 3 months.
Any prior gene therapy.
Study Design
Study Description
Connect with a study center
Belite Study Site
Kobe,
JapanActive - Recruiting
Belite Study Site
Kyoto,
JapanSite Not Available
Belite Study Site
Tokyo,
JapanActive - Recruiting
Bellite Study Site
London,
United KingdomActive - Recruiting
Belite Study Site
Phoenix, Arizona 85020
United StatesSite Not Available
Belite Study Site
La Jolla, California 92093
United StatesActive - Recruiting
Belite Study Site
San Diego, California 92037
United StatesSite Not Available
Belite Study Site
Miami, Florida 33136
United StatesSite Not Available
Belite Study Site
Boston, Massachusetts 02115
United StatesSite Not Available
Belite Study Site
Rochester, Minnesota 55905
United StatesActive - Recruiting
Belite Study Site
Durham, North Carolina 27705
United StatesActive - Recruiting
Belite Study Site
Philadelphia, Pennsylvania 19107
United StatesSite Not Available
Belite Study Site
Dallas, Texas 75231
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.